TDC
ALXN

Thompson Davis & Co’s Alexion Pharmaceuticals ALXN Stock Holding History

Thompson Davis & Co’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-369
Closed -$52K – 1161
2017
Q3 		$52K Sell
369
-206
-36% -$28K 0.09% 230
2017
Q2 		$70K Buy
575
+310
+117% +$36.1K 0.11% 174
2017
Q1 		$32K Sell
265
-11
-4% -$1.42K 0.05% 343
2016
Q4 		$34K Buy
276
+37
+15% +$4.53K 0.06% 318
2016
Q3 		$29K Buy
239
+40
+20% +$5.15K 0.05% 362
2016
Q2 		$23K Sell
199
-2
-1% -$284 0.04% 427
2016
Q1 		$28K Sell
201
-1
-0.5% -$147 0.04% 355
2015
Q4 		$39K Hold
202
– – 0.06% 300
2015
Q3 		$32K Buy
202
+50
+33% +$9.12K 0.04% 347
2015
Q2 		$27K Buy
152
+29
+24% +$5K 0.03% 466
2015
Q1 		$21K Buy
123
+9
+8% +$1.63K 0.03% 520
2014
Q4 		$21K Buy
114
+17
+18% +$3.15K 0.02% 504
2014
Q3 		$16K Buy
+97
New +$15.9K 0.02% 543
2014
Q2 		– Sell
-24
Closed -$4K – 887
2014
Q1 		$4K Sell
24
-750
-97% -$119K 0.01% 685
2013
Q4 		$103K Buy
+774
New +$92.9K 0.16% 150

Other funds holding ALXN

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Thompson Davis & Co's ALXN Position: Q4 2017 in Review

Thompson Davis & Co sold out of Alexion Pharmaceuticals (ALXN) in Q4 2017, closing a stake of 369 shares — an estimated $52K sold.

Thompson Davis & Co first reported a position in ALXN in Q4 2013 and held it in 15 quarters. The position peaked at $103K in Q4 2013. 587 funds tracked by Wall St. Rank hold ALXN as of Q4 2017.

  • Thompson Davis & Co reported no remaining Alexion Pharmaceuticals position as of Q4 2017 after selling out during the quarter.
  • Thompson Davis & Co sold 369 Alexion Pharmaceuticals shares in Q4 2017, an estimated $52K.
  • Thompson Davis & Co first reported a position in Alexion Pharmaceuticals in Q4 2013 and held it in 15 quarters.
  • Thompson Davis & Co's Alexion Pharmaceuticals position peaked at $103K in Q4 2013.
  • 587 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q4 2017.

Based on Thompson Davis & Co's 13F filing for Q4 2017, filed 5 Feb 2018.